Pfizer licensed worldwide rights to its discontinued PF-08046031 (CD228V), an early-stage antibody-drug conjugate originally developed by Seagen, to Medicus Pharma. The agreement includes $12 million upfront, another $15 million due in September 2027, and more than $1 billion in potential development, regulatory, and sales milestones. Pfizer also provided $2 million in development funding and will receive tiered low-double-digit royalties on net sales. Medicus will assume responsibility and costs for developing, manufacturing, securing approval for, and commercializing the ADC. PF-08046031 targets melanotransferrin/CD228, which is highly expressed in melanoma and several solid tumors; there are currently no approved CD228-targeted drugs. Separately, Revolution Medicines reported updated lung-cancer data for its RAS(ON) inhibitor portfolio. In previously treated NSCLC, zoldonrasib showed a preliminary 61% objective response rate and 89% disease-control rate in a small efficacy-eva...
- Get link
- X
- Other Apps